Real-World Effectiveness, Safety, and Health-Related Quality of Life in Patients Receiving Adjuvant Nivolumab for Melanoma in Belgium and Luxembourg: Results of PRESERV MEL.

Rogiers, Anne; Willemot, Laurence; McDonald, Laura; Van Campenhout, Hilde; Berchem, Guy; Jacobs, Celine; Blockx, Nathalie; Rorive, Andrée; Neyns, Bart

Rogiers, Anne; Willemot, Laurence; McDonald, Laura; Van Campenhout, Hilde; Berchem, Guy; Jacobs, Celine; Blockx, Nathalie; Rorive, Andrée; Neyns, Bart.

Afiliação

Rogiers A; Departement of Psychiatry, Centre Hospitalier Universitaire Brugmann, 1020 Brussels, Belgium.
Willemot L; Department of Medical Oncology, Universitair Ziekenhuis Brussel, 1090 Brussels, Belgium.
McDonald L; Faculty of Medicine and Pharmacy Vrije Universiteit Brussel, 1050 Brussels, Belgium.
Van Campenhout H; Bristol Myers Squibb, 1420 Braine L'Alleud, Belgium.
Berchem G; Bristol Myers Squibb, Uxbridge UB8 1DH, UK.
Jacobs C; Bristol Myers Squibb, 1420 Braine L'Alleud, Belgium.
Blockx N; Centre Hospitalier de Luxembourg, University of Luxembourg, 1210 Luxembourg, Luxembourg.
Rorive A; Medical Oncology, Universitair Ziekenhuis Gent, 9000 Gent, Belgium.
Neyns B; Ziekenhuis Netwerk Antwerpen Middelheim, 2020 Antwerp, Belgium.

Cancers (Basel) ; 15(19)2023 Sep 30.

Article em En | MEDLINE | ID: mdl-37835517

Palavras-chave

adjuvant treatment; effectiveness; health-related quality of life; melanoma; nivolumab; real-world; safety

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Idioma: En Revista: Cancers (Basel) Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Bélgica

Texto completo

Adicionar na Minha BVS

Imprimir

XML

PubMed Links

Buscar no Google